Intellia Therapeutics faces March FDA decision for one-time CRISPR HAE therapy
Intellia faces a March 10 FDA decision for lonvo-z after one CRISPR infusion cut HAE attacks 87% in Phase 3 testing.
Pharma & Biotech
Features & Analysis
The liver was the easy organ. Can in-vivo gene editing reach the rest of the human body?
Ex-vivo CRISPR edits cells outside the body before reinfusion. In-vivo editing sends the editing machinery directly into a patient, potentially making treatment simpler but far harder to control.
Pharma & Biotech
Why Intellia’s lonvo-z Phase 3 data could raise expectations for one-time HAE treatment
Find out how Intellia’s lonvo-z Phase 3 data could change expectations for one-time hereditary angioedema treatment.